N-RAS AND K-RAS ONCOGENES IN PLASMA-CELL DYSCRASIAS

被引：23

作者：

CORRADINI, P

LADETTO, M

INGHIRAMI, G

BOCCADORO, M

PILERI, A

机构：

[1] Department of Medicine and Experimental Oncology Division of Hematology, University of Torino

[2] Department of Pathology, New York University

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 15卷 / 1-2期

关键词：

RAS ONCOGENES; PLASMA CELL LEUKEMIA; MULTIPLE MYELOMA; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE;

D O I：

10.3109/10428199409051673

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

N- and K-ras oncogene mutations represent the most frequent molecular lesions in plasma cell dyscrasias. They are not randomly distributed since they are detectable in multiple myeloma (MM) (9-31%) and plasma cell leukemia (PCL) (30%), and not in monoclonal gammopathy of undetermined significance (MGUS) and solitary plasmacytoma (SP). Codons 12, 13 and 61 of N- and K-ras genes have been found mutated. Mutations affecting codon 61 of N-ras gene are the most frequent finding. A heterogeneous pattern of mutations is described with a prevalence of purine-pyrimidine transversions. Ras gene mutations have been predominantly detected in myelomas characterized by an advanced stage disease, and adverse prognostic parameters. These findings suggest that ras mutations represent a late molecular lesion and may be implicated in tumor progression rather than tumor initiation.

引用

页码：17 / 20

页数：4

共 30 条

[21]

Boccadoro M., Marmont F., Tribalto M., Fossati G., Re-Doglia V., Battaglio S., Massaia M., Gallamini A., Comotti B., Barbui T., Campobasso N., Dammacco F., Cantonetti M., Petrucci M.T., Mandelli F., Resegotti L., Pileri A., Early responder myeloma: Kinetic studies identify a patients subgroup characterized by very poor prognosis, J. Clin. Oncol., 7, pp. 119-125, (1989)

[22]

Durie B.G.M., Stock-Novack D., Salmon S.E., Finley P., Beckord J., Crowley J., Coltman C.A., Prognostic value of pretreatment serum beta-2 microglobulin in myeloma: A Southwest Oncology Group Study, Blood, 75, pp. 823-830, (1990)

[23]

Bataille R., Boccadoro M., Klein B., Durie B.G.M., Pileri A., C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system, Blood, 80, pp. 733-737, (1992)

[24]

Bergui L., Schena M., Gaidano G., Riva M., Cali-garis-Cappio F., Interleukin 3 and interleukin 6 syn-ergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma, J. Exp. Med., 170, pp. 613-620, (1989)

[25]

Epstein J., Xiao H., He X.Y., Markers of multiple hematopoietic-cell lineages in multiple myeloma, N. Engl. J. Med., 322, pp. 664-668, (1990)

[26]

Corradini P., Boccadoro M., Voena C., Pileri A., Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C/u sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas, J. Exp. Med., 178, pp. 1091-1096, (1993)

[27]

Seremetis S., Inghirami G., Ferrero D., Newcomb E.W., Knowles D.M., Dotto G.P., Dalla Favera R., Transformation and plasmacytoid differentiation of EBV-in-fected human B lymphoblasts by ras oncogenes, Science, 243, pp. 660-663, (1989)

[28]

Kumar R., Sukumar S., Barbacid M., Activation of ras oncogenes preceding the onset of neoplasia, Science, 248, pp. 1101-1104, (1990)

[29]

Fearon E.R., Vogelstein B., A genetic model for colorectal tumorigenesis, Cell, 61, pp. 759-767, (1990)

[30]

van Kamp H., De Pijper C., Verlaan-de Vries M., Bos J.L., Leeksma C.H.W., Kerkhofs H., Willemze R., Fibbe W.E., Landegent J.E., Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears, Blood, 79, pp. 1266-1270, (1992)

← 1 2 3 →